Nakagawa, M., Inoue, M., Ogasawara, S., Maruta, S., Okubo, T., Itokawa, N., Iino, Y., Obu, M., Haga, Y., Seki, A., Kikuchi, Y., Kogure, T., Yumita, S., Ishino, T., Ogawa, K., Fujiwara, K., Iwanaga, T., Fujita, N., Sakuma, T., Kojima, R., Kanzaki, H., Koroki, K., Taida, T., Kobayashi, K., Kiyono, S., Nakamura, M., Kanogawa, N., Kondo, T., Nakagawa, R., Nakamoto, S., Muroyama, R., Chiba, T., Itobayashi, E., Atsukawa, M., Koma, Y., Azemoto, R., Ito, K., Mizumoto, H., Shinozaki, M., Kato, J., & Kato, N. (2023). clinical effects and emerging issues of atezolizumab plus bevacizumab in patients with advanced hepatocellular carcinoma from Japanese real‐world practice. Cancer, 129(4), 590–599. http://access.bl.uk/ark:/81055/vdc_100174910553.0x000056